Cargando…
WEE1 Inhibitor: Clinical Development
PURPOSE OF REVIEW: WEE1 inhibitor has been shown to potential chemotherapy or radiotherapy sensitivity in preclinical models, particularly in p53-mutated or deficient cancer cells although not exclusively. Here, we review the clinical development of WEE1 inhibitor in combination with chemotherapy or...
Autores principales: | Kong, Anthony, Mehanna, Hisham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285350/ https://www.ncbi.nlm.nih.gov/pubmed/34269904 http://dx.doi.org/10.1007/s11912-021-01098-8 |
Ejemplares similares
-
Development of Effective Siglec-9 Antibodies Against Cancer
por: Wang, Jun Hui Shawn, et al.
Publicado: (2022) -
Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs
por: Joharatnam-Hogan, Nalinie, et al.
Publicado: (2021) -
Chronodisruption and Ambulatory Circadian Monitoring in Cancer Patients: Beyond the Body Clock
por: Almaida-Pagan, Pedro F., et al.
Publicado: (2022) -
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017) -
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
por: Eisen, Tim, et al.
Publicado: (2014)